CURRENT AND FUTURE USE OF RWE IN HTA DECISION-MAKING: PAYERS VIEW GLOBALLY

Dr Sabina Heinz, Market Access Senior Principal, Ipsos

November 2024

© Ipsos | ISPOR presentation: Current and Future Use of RWE in HTA Decision-making | November 2024 | Version 1 | Public Use



Introduction

There are more and more useful data available in addition to RCTs ...



(-) Least robust

Secondary care databases, e.g. Hospital Episode Statistics (HES)

Primary care databases, e.g. general practitioners and family doctors

Surveillance and monitoring data, e.g. drug safety monitoring data

Public health and Social care data

Audits data (clinical practice, registries of the use of medicines, devices, etc.)

Syndicated data captured by market research

Patient-Reported data

Patient organisation data

Real-time data (digital health technologies, including apps and wearables)

Social Media data

© Ipsos | ISPOR presentation: Current and Future Use of RWE in HTA Decision-making | November 2024 | Version 1 | Public Use 2


3 key conditions must generally be met for Real world evidence (RWE) use by HTA bodies:

The data must be: ✓ Available

- ✓ Acceptable
- ✓ Accessible



...and in the recent years, HTA bodies have become increasingly receptive to RWE and their integration into their evaluations



HTA bodies: CDA-AMC: Canada's Drug Agency; HAS: Haute Autorité de Santé; IQWiG: Institute for Quality and Efficiency in HealthCare; NICE: National Institute for Health and Care Excellence; EU Health Technology Assessment Regulation Regulatory bodies: MDA: Pharmaceuticals and Medical Devices Agency; TGA: Therapeutic Goods Administration; HSA: Health Sciences Authority; NMPA: National Medical Products Administration;

© Ipsos | ISPOR presentation: Current and Future Use of RWE in HTA Decision-making | November 2024 | Version 1 | Public Use 3

Introduction

Methodology

We fielded an online survey with payers from the lpsos payer panel across EU and non-EU member states



To explore the **payer perspective regarding the challenges and opportunities associated with integrating Real-World Evidence (RWE)** into evidence submissions for reimbursement decisionmaking by HTA bodies, both in the present and future contexts.



lpsos carried out an **online survey targeting payers**, utilizing a brief questionnaire

Objective



- **Topics**
- RWE Guidelines
- Barriers to Adoption and concerns
- Importance in reimbursement decisions
 - **Applications** in Decision-Making
 - Benefiting **Treatments**
 - Preferred Data Sources






Sample


Canada, France, Germany, Italy, UK, Spain, Belgium, Denmark, Portugal

Scope countries



EU countries with less developed RWE guidelines or frameworks often rely on international ones while developing their own national guidelines






There is an increased emphasis on future data generation and AI usage, alongside efforts to digitalize data through national platforms in FR & IT

Results

Data quality, transparency, and source are identified as primary barriers, with study methodology and data handling expertise also posing issues






80%

78%


Payers value RWE mostly for ITC, mainly in chronic or rare diseases, and prefer data from pragmatic trials, registries, and observational studies



Other EU markets don't see its value in ITC and in ES don't see it in selection of clinical trials endpoints and population; FR & DE don't see its value into economic evaluation for QALY calculation Additional sources suggested, ordered by preference, include Observational studies (50%) Electronic Health Records (44%), Administrative Claims (39%), Health Surveys (11%), Patient-Generated Health Data (11%), and Interviews & Focus Group Discussions (6%).



Payers are divided on RWE importance, which is believed to potentially influence reimbursement, though reliance solely on RWE is likely limited





To enhance the integration of RWE into HTAs, establishing trust, clear standards, and utilizing relevant data tailored to specific questions is key



Enhanced Data Integration

Payers' concerns about RWE can be overcome by **building trust in the quality, transparency, and source of RWD**. By addressing potential biases in observational data, using appropriate statistical techniques may ensure some level of transparency in the analysis process.

Addressing Key Questions

Pragmatic trials and registries are often preferred for RWE because of their higher acceptance rates. Payers have concerns about data quality, study design, and potential bias in RWE studies. **Clear guidelines and standards for using RWE are still needed, and education on evaluating and interpreting RWE** is crucial for payers. Although guidelines can be helpful, they are still under development in many regions, highlighting the need for **continued discussion and collaboration**.

RWE's Evolving Role

While RWE primarily complements RCTs, it offers a cost-effective approach to address uncertainties and provide supplemental data. Payers are increasingly recognizing the value of RWE, but its use as the sole evidence for reimbursement decisions remains limited.



THANK YOU

Dr Sabina Heinz, Chitresh Kumari, Joao Ataide, Maria Bourakkadi, Giovanna Castellano

Sabina.Heinz@lpsos.com

© Ipsos | ISPOR presentation: Current and Future Use of RWE in HTA Decision-making | November 2024 | Version 1 | Public Use

